- Home
- PRGO vs VRNA Comparison
PRGO vs VRNA Comparison
Compare PRGO & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGO
- VRNA
- Stock Information
- Founded
- PRGO 1887
- VRNA 2005
- Country
- PRGO Ireland
- VRNA United Kingdom
- Employees
- PRGO N/A
- VRNA N/A
- Industry
- PRGO Biotechnology: Pharmaceutical Preparations
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- PRGO Health Care
- VRNA Health Care
- Exchange
- PRGO Nasdaq
- VRNA Nasdaq
- Market Cap
- PRGO 3.3B
- VRNA 3.4B
- IPO Year
- PRGO 1991
- VRNA 2017
- Fundamental
- Price
- PRGO $25.34
- VRNA $67.96
- Analyst Decision
- PRGO Buy
- VRNA Strong Buy
- Analyst Count
- PRGO 4
- VRNA 7
- Target Price
- PRGO $35.00
- VRNA $57.14
- AVG Volume (30 Days)
- PRGO 1.1M
- VRNA 1.3M
- Earning Date
- PRGO 02-27-2025
- VRNA 02-27-2025
- Dividend Yield
- PRGO 4.36%
- VRNA N/A
- EPS Growth
- PRGO N/A
- VRNA N/A
- EPS
- PRGO N/A
- VRNA N/A
- Revenue
- PRGO $4,392,000,000.00
- VRNA $5,624,000.00
- Revenue This Year
- PRGO N/A
- VRNA N/A
- Revenue Next Year
- PRGO $4.56
- VRNA $571.44
- P/E Ratio
- PRGO N/A
- VRNA N/A
- Revenue Growth
- PRGO N/A
- VRNA 1127.95
- 52 Week Low
- PRGO $23.14
- VRNA $11.39
- 52 Week High
- PRGO $33.46
- VRNA $68.64
- Technical
- Relative Strength Index (RSI)
- PRGO 56.23
- VRNA 76.88
- Support Level
- PRGO $23.86
- VRNA $62.24
- Resistance Level
- PRGO $24.89
- VRNA $65.50
- Average True Range (ATR)
- PRGO 0.57
- VRNA 2.78
- MACD
- PRGO 0.11
- VRNA 0.22
- Stochastic Oscillator
- PRGO 86.55
- VRNA 94.86
About PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.